Quetiapine

is prescribed to treat:

• Schizophrenia, bipolar disorder, and depression augmentation • Various related conditions in the mental health category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Quetiapine (Seroquel) is an atypical antipsychotic used for schizophrenia, for bipolar disorder in both manic and depressive phases, and as adjunctive treatment in major depressive disorder. It is also very widely prescribed off-label at low doses for insomnia and anxiety — a practice that accounts for a large share of its use and that deserves direct scrutiny.

Mechanism of Action

Quetiapine antagonises dopamine D2 and serotonin 5-HT2A receptors, the combination that defines atypical antipsychotics. Its D2 binding is comparatively loose and rapidly dissociating, which is thought to explain its low rate of extrapyramidal side effects and tardive dyskinesia relative to typical antipsychotics and to some other atypicals such as risperidone.

Its receptor profile is broad, and the effects are strikingly dose-dependent — quetiapine behaves almost like different drugs at different doses. At low doses, potent histamine H1 antagonism dominates, producing marked sedation with minimal antipsychotic activity. At intermediate doses, the active metabolite norquetiapine adds norepinephrine transporter inhibition and 5-HT2C antagonism, which underlies the antidepressant effect in bipolar depression. Only at higher doses does D2 occupancy reach the range associated with antipsychotic efficacy.

This explains why 25 to 50 mg at night is a sedative rather than a treatment for psychosis, and why the doses used for schizophrenia are many times higher. It also explains the alpha-1 antagonism responsible for orthostatic hypotension, which drives the need for gradual titration.

The Off-Label Insomnia Question

Low-dose quetiapine for insomnia is common because it works: it is strongly sedating, is not a controlled substance, and carries no dependence risk of the kind associated with benzodiazepines or zolpidem.

The difficulty is that the metabolic risks of an antipsychotic do not scale down as neatly as the sedation does. Weight gain, dyslipidemia, and impaired glucose tolerance occur at low doses, and patients taking it nightly for years accumulate that exposure for a sleep indication that has better-evidenced and safer alternatives — cognitive behavioural therapy for insomnia being first-line and more durable than any medication. Evidence for quetiapine in primary insomnia is thin, and it is not approved for it.

That does not make the practice indefensible in every case, but it does mean the trade should be explicit rather than default. A patient started on it in hospital for sleep and still taking it three years later, with no psychiatric indication and a 20-pound weight gain, is a common and avoidable pattern. Our psychiatric team reviews these regimens, and the MedlinePlus quetiapine entry covers prescribing detail.

Clinical Use

For its approved indications quetiapine is genuinely valuable. It is one of the few agents with good evidence in bipolar depression, a phase that is harder to treat than mania and where antidepressants alone risk precipitating a switch into mania. It is effective in acute mania and in maintenance, and in schizophrenia it is a reasonable option particularly where extrapyramidal effects have been a problem with other agents.

Titration is gradual, both to limit orthostatic hypotension and to allow the marked initial sedation to accommodate. The extended-release formulation permits once-daily dosing and is somewhat less sedating at equivalent doses. Because it is not a controlled substance and is highly sedating, quetiapine is diverted and misused in some settings despite having no euphoric effect.

Monitoring and Follow-Up

Metabolic monitoring is the central requirement and is frequently neglected, especially when the drug was started for sleep rather than by a psychiatrist. Weight and BMI should be recorded at baseline and tracked; waist circumference, fasting glucose or hemoglobin A1c, and a lipid panel should be checked at baseline, at three months, and at least annually thereafter.

Weight gain is often substantial and is among the most common reasons patients stop. Addressing it early — through diet and activity counselling, or by reconsidering the drug — works better than waiting until 30 pounds have accumulated. The visceral fat article explains why the pattern of gain matters.

Blood pressure should be checked sitting and standing during titration given the orthostatic effect. Quetiapine prolongs the QT interval modestly, so an ECG is worth obtaining in patients with cardiac disease, electrolyte disturbance, or other QT-prolonging drugs. Extrapyramidal symptoms and tardive dyskinesia are less frequent than with typical antipsychotics but still occur and should be examined for periodically. Sedation, dry mouth, constipation, and dizziness are common early and often improve. The National Institute of Mental Health provides patient-level background.

Special Populations

Antipsychotics carry a boxed warning of increased mortality in elderly patients with dementia-related psychosis, and quetiapine is not approved for that use. Where behavioural symptoms in dementia genuinely require medication after non-pharmacologic approaches have failed, it is used at the lowest dose for the shortest period with the risk explicitly documented.

In older adults generally, start low and titrate slowly given falls risk from sedation and orthostatic hypotension. Hepatic impairment slows clearance and requires reduced dosing; kidney impairment does not. In pregnancy, quetiapine is used when the psychiatric indication warrants it, since untreated severe mental illness carries substantial risk. Quetiapine is metabolised by CYP3A4, so strong inhibitors raise levels and strong inducers lower them meaningfully.

When to Contact Your Doctor

Seek emergency care for high fever with muscle rigidity, confusion, and autonomic instability, which suggests neuroleptic malignant syndrome. Report uncontrollable movements of the face, tongue, or limbs, which may indicate tardive dyskinesia and can become permanent if the drug is continued. Fainting or near-fainting warrants review of the dose and titration.

Report substantial weight gain, increased thirst or urination, or new symptoms of diabetes. New or worsening thoughts of self-harm, or a switch into unusually elevated mood, should be reported promptly. If you take quetiapine only for sleep, ask whether it is still the right choice — that conversation is worth having rather than continuing by default.

To review your dose, your metabolic monitoring, or whether quetiapine is still the right medication for you, contact us or schedule a visit.